Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 12, 2026
Gossamer Bio, Inc. (GOSS)
A forensic read on Gossamer Bio, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-11.3
Distress distance
Watch
Earnings quality
3
Forensic signals
-18.8
P / E (ttm)
$5.2B
Market cap
0.00%
Dividend yield
-57.7%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Gossamer Bio, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -11.3, placing it in the Distress zone. 3 forensic signals were flagged in its latest SEC filings, led by receivables vs revenue.
What the filings flag
92d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 17 to 92 days FY2024→FY2025 (receivables +129% vs revenue -58%). Receivables grew, but deferred revenue grew +17% over the same period too — rising alongside rising unearned revenue reads as upfront billing on multi-period contracts, not slipping collections. There's no FY2023 figure on file for receivables, so FY2024 has no opening balance to average against — both figures are measured on period-end balances rather than the beginning-plus-ending average, since averaging only the current year would make the move track balance-sheet growth rather than the business.
n/m (stock split)
FY2022–FY2025
Share count (stock split).Diluted share count changed +170% over the last 3 years to FY2025, but that includes a large one-time change around FY2023 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +39.3%/yr figure isn't a real buyback/dilution read here.
22% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 22% of revenue in FY2025 — about $0.05 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 20.7% a year, and the rate is falling. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
Key fundamentals
Latest Revenue$48.5M
Revenue Growth YoY-57.7%
Net Margin-351.5%
Free Cash Flow-$171.3M
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Gossamer Bio, Inc.'s actual 10-K/10-Q/8-K filings?